New ways to successfully target tumor vasculature in ovarian cancer

Xiaoyun Yang, Fangrong Shen, Wei Hu, Robert L. Coleman, Anil K. Sood

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

PURPOSE OF REVIEW: The aim of this article was to review the recent literature on potential therapeutic strategies for overcoming resistance to antivascular endothelial growth factor drugs in ovarian cancer. RECENT FINDINGS: Although clinical benefits of antivascular endothelial growth factor therapy were observed in ovarian cancer treatment trials, this use yielded only modest improvement in progression-free survival and, with the exception of cediranib, no effect on overall survival. Adaptive resistance and escape from antiangiogenesis therapy is likely a multifactorial process, including induction of hypoxia, vascular modulators, and immune response. New drugs targeting the tumor vasculature or other components of the surrounding microenvironment have shown promising results. SUMMARY: When to start and end antiangiogenesis therapy and the choice of optimal treatment combinations remain controversial. Further evaluation of personalized novel angiogenesis-based therapy is warranted. Defining the critical interaction of these agents and pathways and the appropriate predictive markers will become an increasingly important objective for effective treatment.

Original languageEnglish (US)
Pages (from-to)58-65
Number of pages8
JournalCurrent Opinion in Obstetrics and Gynecology
Volume27
Issue number1
DOIs
StatePublished - Feb 13 2015

Keywords

  • adaptive resistance
  • angiogenesis
  • ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'New ways to successfully target tumor vasculature in ovarian cancer'. Together they form a unique fingerprint.

Cite this